Full Press Release Details
CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC ) today announced leadership transitions for the company's research and development organization. Effective as of January 11, 2021 , Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral , M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and biostatistics. In his new role, Dr. Boral will advise on clinical development, regulatory and business development strategy across the company's portfolio. Drs. Hewes and Boral will report to Fouad Namouni, M.D., President, Research & Development.
In addition, Marion Dorsch , Ph.D., has notified the company of her intention to resign as the company's Chief Scientific Officer to pursue other career opportunities. Her resignation will be effective March 1, 2021 , and the company has initiated a search for her replacement.
About Becker Hewes
Dr. Hewes brings 20 years of industry and clinical experience in oncology and hematology, including achieving the approval of three tyrosine kinase inhibitors. Previously, he served as Blueprint Medicines' Senior Vice President, Clinical Development from May 2020 to January 2021 . Prior to joining Blueprint Medicines, Dr. Hewes served as Chief Medical Officer of Repertoire Immune Medicines (formerly Torque Therapeutics) from February 2017 to May 2020 , where he built Repertoire's multidisciplinary clinical and biomarker team and advanced its lead immuno-oncology programs into clinical development. From June 2013 to February 2017 , Dr. Hewes served as Executive Director of Translational Clinical Oncology at the Novartis Institutes for BioMedical Research where he led clinical development and translational medicine efforts for multiple early-stage oncology programs through clinical proof-of-concept, including Kisqali® (ribociclib), a targeted therapy approved to treat breast cancer, and other programs combining novel therapies. Prior to that, he held roles of increasing responsibility related to clinical development in oncology and hematology within AstraZeneca PLC, Genzyme Corporation and Wyeth Pharmaceuticals, including leading registration programs for Bosulif® (bosutinib) and Torisel® (temsirolimus) for chronic myelogenous leukemia and mantle cell lymphoma, respectively. Before joining industry, he conducted immuno-oncology research at the Emory Vaccine Center while treating patients as a pediatric oncologist at Children's Healthcare of Atlanta . Dr. Hewes holds an M.D. from the Georgetown University School of Medicine and a B.S. from Vanderbilt University .
About Blueprint Medicines
Blueprint Medicines, AYVAKIT and associated logos are trademarks of Blueprint Medicines Corporation.
SOURCE Blueprint Medicines Corporation